QV Bioelectronics is pleased to announce a leadership transition as the company enters its next phase of growth and clinical development.
Carl Daintree has assumed the role of Chief Executive Officer. Carl brings extensive cross-functional experience across the medical device, pharmaceutical and biotechnology sectors, along with a strong track record of advancing complex technologies from early-stage development through clinical evaluation and into commercialisation.
Christopher Bullock, Co-Founder of QV Bioelectronics, will transition from Chief Executive Officer to Chief Technology Officer. In this role, Chris will continue to lead the company’s scientific and technical strategy, focusing on the advancement of its bioelectronic platform for the treatment of brain tumours.
As Co-Founder, Chris has played a central role in establishing QV Bioelectronics and developing the core technology underpinning its mission. This transition enables him to dedicate greater focus to innovation and product development, while Carl leads the organisation through its clinical phase and towards regulatory approval.
This leadership evolution reflects QV Bioelectronics’ continued progress and ambition as it works to bring novel, effective treatment options to patients living with devastating brain cancers.